Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery
Open Access
- 1 January 2016
- journal article
- Published by Elsevier BV in Molecular Therapy - Methods & Clinical Development
- Vol. 3, 16036
- https://doi.org/10.1038/mtm.2016.36
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal DiseaseMolecular Therapy, 2013
- Ocular manifestations as key features for diagnosing mucopolysaccharidosesRheumatology, 2011
- Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs—A proof of principle studyMolecular Genetics and Metabolism, 2009
- Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor NeuronsMolecular Therapy, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Effect of high dose, repeated intra‐cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA miceGenes, Brain and Behavior, 2008
- Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic InjectionMolecular Therapy, 2008
- Development of Sensory, Motor and Behavioral Deficits in the Murine Model of Sanfilippo Syndrome Type BPLOS ONE, 2007
- Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesisGene Therapy, 2001
- A fluorimetric enzyme assay for the diagnosis of sanfilippo disease type A (MPS IIIA)Journal of Inherited Metabolic Disease, 1995